Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Paclitaxel + Encequidar vs IV Paclitaxel in HER2- Metastatic Breast Cancer
NCT06835400Phase 3Not yet recruiting
- Sponsor
- Health Hope Pharma
- Start
- Sep 2025
- Primary completion
- Apr 2028
- Modality
- Cytokines & Interferons, Small Molecules, Fc-Fusion Proteins
01
Overview
Phase 3, randomised, open-label trial of Paclitaxel Micelles for Injection and encequidar in breast cancer (4 arms), sponsored by Health Hope Pharma. Primary endpoints: Confirmed Tumor Response (Stage 1) at 6 months and Confirmed Tumor Response (Stage 2) at 1 year. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
Paclitaxel Micelles for Injectionencequidar
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06835400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06835400.